Migraine Market

Key Findings

  • The total Migraine prevalent population in the 7MM was 118,491,327 cases in 2021.
  • In 2021, the Migraine market size in the seven major markets was found to be USD 6,960.14 million in 2021, which is expected to grow by 2032.
  • Some of the key companies in the Migraine Market include Lundbeck Seattle BioPharmaceutical, Eli Lilly and Company, Amgen, Novartis, Teva Pharmaceuticals, Allergan, Biohaven Pharmaceuticals, Ionis Pharmaceuticals, Inc., Charleston Laboratories, and others.

 

Request for sample pages to learn more about the market CAGR and key trends Migraine Market 

 

DelveInsight’s ‘Migraine Market Insights, Epidemiology and Market Forecast—2032’ report delivers an in-depth understanding of the Migraine, historical and forecasted epidemiology as well as the market trends in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

 

The Migraine market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Migraine symptoms market size from 2019 to 2032 segmented by the seven major markets. The report also covers current Migraine symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • The EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Migraine Understanding and Treatment Algorithm

Migraine Overview

Migraine is ranked globally as the seventh most disabling disease among all diseases (responsible for 2.9% of all years of life lost to disability/YLDs) and the leading cause of disability among all neurological disorders.

 

It includes severe throbbing recurring pain, usually on one side of the head, often accompanied by visual disturbances, nausea, vomiting, dizziness, extreme sensitivity to sound, light, touch and smell, and tingling or numbness in the extremities or face; although symptoms usually include a severe throbbing recurring pain on one side of the head, yet in one-third of migraine attacks, both sides are found to be affected.

 

Migraine is classified by the nature of the attack and its frequency as chronic and episodic migraine. Episodic migraine is characterized by those with migraine who have 0–14 headache days per month, while chronic migraine is characterized by 15 or more headache days per month.

 

Migraine remains undiagnosed and undertreated in at least ~ 50% of patients, and less than 50% of migraine patients consult a physician.

 

Treatment can be acute or preventive. Acute treatment is initiated during an attack to alleviate pain and disability and to stop the progression of the attack. Preventive treatment is used when there exists a known headache trigger, such as exercise or sexual activity, and for patients who have limited time exposure to a trigger, such as high-altitude ascent or menstruation.

 

The overall dynamics of the Migraine market is anticipated to change in the coming years owing to the expected launch of emerging therapies and others are developing treatments for Migraine.

 

Migraine Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Migraine market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, the Europe, and Japan.

 

The DelveInsight Migraine market report gives a thorough understanding of Migraine symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Migraine algorithms and treatment guidelines in the US, the Europe, and Japan.

Migraine Epidemiology

The epidemiology division’s Migraine symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major country. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Migraine epidemiology segmented as the Total Prevalence of Migraine, Prevalent Cases of Migraine based on severity, Gender specific Prevalence of Migraine, and Diagnosed Cases of Chronic and Episodic Migraine. The report includes the Migraine scenario in the 7MM, covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Migraine Market Assessment and Epidemiology

Country Wise-Migraine Epidemiology

The epidemiology segment also provides the Migraine epidemiology data and findings across the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The total 7MM prevalent population of Migraine were 118,491,327 cases in 2021.

Migraine Drug Chapters

The drug chapter segment of the Migraine report encloses the detailed analysis of Migraine marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Migraine clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Products detail in the report…

 

Migraine Emerging Drugs

 

INP104 (Impel NeuroPharma)

Impel NeuroPharma is currently developing INP104 intending to be a transformative new therapy for acute migraine. INP104 utilizes Impel’s propellant-enabled POD technology to conveniently and consistently deliver optimal doses of DHE deep into the vascular rich upper nasal space, an ideal target for efficient drug administration, particularly for the majority of patients with migraine who experience nausea and/or vomiting during an attack, which presents limitations for the use of oral therapies, including triptans, CGRP inhibitors, and ditans as well as other non-specific acute migraine medications.

Products detail in the report…

Migraine Market Outlook

Migraine Market Outlook

The Migraine market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Migraine market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

 

This segment gives a thorough detail of Migraine market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, Migraine market in the 7MM is expected to change in the study period 2019-2032.

 

Key Findings

This section includes a glimpse of the Migraine market in the 7MM. The market size of Migraine in the seven major markets was found to be USD 6,960.14 million in 2021.

 

The United States Market Outlook

This section provides a total of Migraine market size and market size by therapies in the United States.

 

The United States accounts for higher Migraine market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

 

The EU-5 Countries: Market Outlook

The total Migraine market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook

The total Migraine market size and market size by therapies in Japan are also mentioned.

Migraine Market Assessment

Migraine Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019-2032. The analysis covers Migraine market uptake by drugs, patient uptake by therapies, and drug sales.

 

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.

Migraine Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Migraine key players involved in developing targeted therapeutics.

 

Major players BHV-3500 (Zavegepant) (Biohaven Pharmaceuticals), Atogepant (AbbVie), Zolmitriptan transdermal (Zosano Pharma), AXS-07 (Axsome Therapeutics), and others are being assessed as potential therapies to be available in the market in the coming future.

 

Migraine Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Migraine emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working on Migraine domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapy treatment patterns or Migraine market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Migraine Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Report Metrics

Details

Study Period

2019 to 2032

Base Year

2021

Forecast Period

2022 to 2032

CAGR

Request Sample to Know

Market Size

USD 6,960.14 Million in 2021

Key Companies

Lundbeck Seattle BioPharmaceutical, Eli Lilly and Company, Amgen, Novartis, Teva Pharmaceuticals, Allergan, Biohaven Pharmaceuticals, Dr. Reddy’s Labs, AbbVie, Impel NeuroPharma, Zosano Pharma, Axsome Therapeutics, Aeon Biopharma Inc., Ionis Pharmaceuticals, Inc., Charleston Laboratories, and others

Scope of the Report

  • The report covers the descriptive overview of Migraine explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Migraine epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Migraine provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Migraine market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Migraine market

Report Highlights

  • In the coming years, Migraine market is set to change due to the rising awareness of the disease, resistant to the current antibiotic regime, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Migraine R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Migraine. The launch of emerging therapies will significantly impact the Migraine market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Migraine
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II and Phase III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Migraine Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Migraine Pipeline Analysis
  • Migraine Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Migraine Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Migraine Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Migraine Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Migraine Market share (%) distribution in 2022, and how would it look in 2032?
  • What would be the Migraine total market Size as well as market Size by therapies across the 7MM during the forecast period (2022–2032)?
  • What are the market key findings across 7MM, and which country will have the largest Migraine market Size during the forecast period (2022–2032)?
  • At what CAGR, the Migraine market is expected to grow by 7MM during the forecast period (2022–2032)?
  • What would be the Migraine market outlook across the 7MM during the forecast period (2022–2032)?
  • What would be the Migraine market growth till 2032, and what will be the resultant market size in the year 2032?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Migraine?
  • What is the historical Migraine patient pool in the seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Migraine in the seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Migraine?
  • Out of all the 7MM countries, which country would have the highest prevalent Migraine population during the forecast period (2022–2032)?
  • At what CAGR is the population expected to grow by 7MM during the forecast period (2022–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Migraine?
  • What are the current treatment guidelines for treating Migraine in the US, the Europe, and Japan?
  • What are the Migraine marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Migraine?
  • How many therapies are developed by each company for the treatment of Migraine?
  • How many emerging therapies are in the mid-stage and late development stages to treat Migraine?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Migraine therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Migraine and their status?
  • What are the key designations that have been granted for the emerging therapies for Migraine?
  • What are the global historical and forecasted markets of Migraine?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Migraine market
  • To understand the future market competition in the Migraine market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Migraine in the US, the Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Migraine market
  • To understand the future market competition in the Migraine market

Frequently Asked Questions

What is Migraine?
Migraine is severe throbbing recurring pain, usually on one side of the head, often accompanied by visual disturbances, nausea, vomiting, dizziness, extreme sensitivity to sound, light, touch and smell, and tingling or numbness in the extremities or face; although symptoms usually include a severe throbbing recurring pain on one side of the head, yet in one-third of migraine attacks, both sides are found to be affected
What is the Migraine Market Size in 7MM?
The Migraine Market Size in the 7MM was found to be USD 6,960.14 Million in 2021
At what CAGR is the Migraine Market expected to grow by 2032?
The Migraine Market Size was USD 6,960.14 Million in 2021, and it is expected to grow at a significant CAGR by 2032
Which country will grab the maximum Migraine Market share among the 7MM?
The United States is expected to hold the major market share among the 7MM countries during the forecast period (2022-32)
How many prevalent cases of Migraine were recorded in the 7MM?
The total prevalent population of Migraine in the 7MM were 118,491,327 in 2021
Which country is expected to account for the most significant prevalent cases of Migraine in the 7MM?
The United States is anticipated to account for the highest prevalent cases of Migraine cases among the 7MM during the forecast period
Which are the leading companies in the Migraine Market Landscape?
The key companies in the Migraine Market include Lundbeck Seattle BioPharmaceutical, Eli Lilly and Company, Amgen, Novartis, Teva Pharmaceuticals, Allergan, Biohaven Pharmaceuticals, Dr. Reddy’s Labs, AbbVie, Impel NeuroPharma, Zosano Pharma, Axsome Therapeutics, Aeon Biopharma Inc., Ionis Pharmaceuticals, Inc., Charleston Laboratories, and others
What are the key strengths of the Migraine Market Report?
The key strengths of the Migraine Market Report are 11 Years Forecast, 7MM Coverage, Epidemiology Segmentation, Market Size, Drug Uptake, Pipeline Therapies, Market Drivers, and Market Barriers, along with the upcoming market trends in the Migraine Market

1. Key Insights

2. Report Introduction

3. Migraine Market Overview at a Glance

3.1. Market Share (%) Distribution of Migraine in 2019

3.2. Market Share (%) Distribution of Migraine in 2032

4. Executive Summary of Migraine

5. Disease Background and Overview

5.1. Introduction

5.2. Symptoms

5.3. Cause

5.4. Risk Factors

5.5. Types of Migraine

5.6. Migraine With/Without Aura

5.7. Pathophysiology

5.8. Diagnosis

6. Treatment

6.1. American Headache Society Guidelines for Migraine

6.2. Guideline by Chronic Headache Clinical Practice Development Committee of Japan

6.3. Nice Guidelines for Migraine Management

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. 7MM Total Prevalent Patient Population of Migraine

7.3. Epidemiology of Migraine

7.4. The United States

7.4.1. Prevalence of Migraine in the United States

7.4.2. Prevalent Cases of Migraine by severity in the United States

7.4.3. Gender-specific Prevalence of Migraine in the United States

7.4.4. Diagnosed Cases of Episodic and Chronic Migraine in the United States (000’s)

7.5. The EU-5

7.5.1. Prevalence of Migraine in the EU5

7.5.2. Prevalent Cases of Migraine by severity in the EU-5

7.5.3. Gender-specific Prevalence of Migraine in the EU5

7.5.4. Diagnosed Cases of Episodic and Chronic Migraine in the EU5

7.6. Japan

7.6.1. Prevalence of Migraine in Japan

7.6.2. Prevalent Cases of Migraine based on Severity in Japan

7.6.3. Gender-specific Prevalence of Migraine in Japan (in 000’s)

7.6.4. Diagnosed Cases of Episodic and Chronic Migraine in Japan

8. Patient Journey

9. Patient Journey

10. Marketed Therapies

10.1. Vyepti (Eptinezumab): Lundbeck Seattle BioPharmaceutical

10.1.1. Drug Description

10.1.2. Regulatory Milestones

10.1.3. Safety and Efficacy

10.1.4. Product Profile

10.2. Emgality (Galcanezumab-gnlm): Eli Lilly and Company

10.2.1. Product Description

10.2.2. Mechanism of action

10.2.3. Regulatory Milestones

10.2.4. Safety and Efficacy of Emgality

10.2.5. Product Profile

10.3. Aimovig: Amgen/Novartis

10.3.1. Product Description

10.3.2. Mechanism of action

10.3.3. Regulatory Milestones

10.3.4. Other Developmental Activities

10.3.5. Clinical Development

10.3.6. Safety and Efficacy

10.3.7. Product Profile

10.4. Ajovy: Teva Pharmaceuticals

10.4.1. Product Description

10.4.2. Mechanism of action

10.4.3. Regulatory Milestones

10.4.4. Other developmental Activities

10.4.5. Clinical Development

10.4.6. Safety and Efficacy

10.4.7. Product Profile

10.5. Ubrelvy: Allergan

10.5.1. Product Description

10.5.2. Regulatory Milestones

10.5.3. Safety and Efficacy

10.5.4. Product Profile

10.6. Rimegepant (Nurtec ODT): Biohaven Pharmaceuticals

10.6.1. Product Description

10.6.2. Regulatory Milestones

10.6.3. Clinical Development

10.6.4. Safety and Efficacy

10.6.5. Product Profile

10.7. Tosymra nasal spray: Dr. Reddy’s Labs

10.7.1. Product Description

10.7.2. Mechanism of action

10.7.3. Regulatory Milestones

10.7.4. Safety and Efficacy

10.7.5. Product Profile

10.8. Reyvow: Eli Lilly and Company

10.8.1. Product Description

10.8.2. Mechanism of action

10.8.3. Regulatory Milestones

10.8.4. Safety and Efficacy

10.8.5. Product Profile

10.9. Botox:  Allergan

10.9.1. Product Description

10.9.2. Regulatory Milestones

10.9.3. Safety and Efficacy

10.9.4. Product Profile

11. Emerging Therapies

11.1. BHV-3500 (Zavegepant): Biohaven Pharmaceuticals

11.1.1. Drug Description

11.1.2. Clinical Development

11.1.3. Clinical Trials Information

11.1.4. Safety and Efficacy

11.1.5. Product Profile

11.1.6. Analysts’ Views

11.2. Atogepant: AbbVie

11.2.1. Drug Description

11.2.2. Clinical Development

11.2.3. Clinical Trials Information

11.2.4. Safety and Efficacy

11.2.5. Product Profile

11.2.6. Analysts’ Views

11.3. INP104: Impel NeuroPharma

11.3.1. Drug Description

11.3.2. Other Developmental Activities

11.3.3. Clinical Development

11.3.4. Clinical Trials Information

11.3.5. Safety and Efficacy

11.3.6. Product Profile

11.3.7. Analysts’ Views

11.4. Zolmitriptan transdermal: Zosano Pharma

11.4.1. Drug Description

11.4.2. Other Developmental Activities

11.4.3. Clinical Development

11.4.4. Clinical Trials Information

11.4.5. Safety and Efficacy

11.4.6. Product Profile

11.4.7. Analysts’ Views

11.5. AXS-07: Axsome Therapeutics

11.5.1. Drug Description

11.5.2. Clinical Development

11.5.3. Clinical Trials Information

11.5.4. Safety and Efficacy

11.5.5. Product Profile

11.5.6. Analysts’ Views

11.6. Lu AG09222: Lundbeck

11.6.1. Drug Description

11.6.2. Clinical Development

11.6.3. Clinical Trials Information

11.6.4. Product Profile

11.6.5. Analysts’ Views

11.7. ABP-450: Aeon Biopharma Inc.

11.7.1. Drug Description

11.7.2. Clinical Development

11.7.3. Clinical Trials Information

11.7.4. Product Profile

11.7.5. Analyst Views

11.8. IONIS-PKKRx: Ionis Pharmaceuticals, Inc.

11.8.1. Drug Description

11.8.2. Clinical Development

11.8.3. Clinical Trials Information

11.8.4. Product Profile

11.8.5. Analyst Views

11.9. Oral CL-H1T: Charleston Laboratories

11.9.1. Drug Description

11.9.2. Clinical Development

11.9.3. Clinical Trials Information

11.9.4. Product Profile

11.9.5. Analyst Views

11.10. LY-3451838: Eli Lilly and Company

11.10.1. Drug Description

11.10.2. Clinical Development

11.10.3. Clinical Trials Information

11.10.4. Product Profile

11.10.5. Analyst Views

12. Migraine: 7 Major Market Analysis

12.1. Key Findings

12.2. Market Size of Migraine in 7MM

13. Market Outlook

13.1. Assumption and Rationale

13.2. United States Market Size

13.2.1. Total Market Size of Migraine in United States

13.2.2. Market Size of Episodic Migraine for preventive Therapies in United States

13.2.3. Market Size of Episodic Migraine for Acute Therapies in United States

13.2.4. Market Size of Chronic Migraine for preventive Therapies in United States

13.2.5. Market Size of Chronic Migraine for Acute therapies in United States

13.3. The EU-5 Market Size

13.3.1. Total Market size of Migraine in the EU-5

13.3.2. Market Size of Episodic Migraine for preventive Therapies in the EU-5

13.3.3. Market Size of Episodic Migraine for Acute Therapies in the EU-5

13.3.4. Market Size of Chronic Migraine for preventive Therapies in the EU-5

13.3.5. Market Size of Chronic Migraine for Acute Therapies in the EU-5

13.4. Japan

13.4.1. Total Market size of Migraine in Japan

13.4.2. Market Size of Episodic Migraine for preventive Therapies in Japan

13.4.3. Market Size of Episodic Migraine for Acute Therapies in Japan

13.4.4. Market Size of Chronic Migraine for preventive Therapies in Japan

13.4.5. Market Size of Chronic Migraine for Acute Therapies in Japan

14. KOL Views

15. Unmet Needs

16. SWOT Analysis

17. Appendix

17.1. Bibliography

17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Table

Table 1: Summary of Migraine, Market, Epidemiology, and Key Events (2019–2032)

Table 2: Patient Characteristics of EM vs. CM

Table 3: ICHD-3 (Beta) Criteria for Migraine With Aura

Table 4: ICHD-3 (Beta) Criteria for Migraine Without Aura

Table 5: ICHD-3 (Beta) Diagnostic Criteria for CM

Table 6: Differential Diagnosis of Primary Chronic Headache of Long Duration

Table 7: Total Prevalent Patient Population of Migraine in 7MM (2019–2032)

Table 8: Prevalence of Migraine in the United States (2019–2032)

Table 9: Prevalent Cases of Migraine based on severity in the United States (2019–2032)

Table 10: Gender-specific Prevalence of Migraine in the United States (2019–2032)

Table 11: Diagnosed Cases of Episodic and Chronic Migraine in the United States (2019–2032)

Table 12: Prevalence of Migraine in the EU5 (2019–2032)

Table 13: Prevalent Cases of Migraine by severity in the EU-5 (2019–2032)

Table 14: Gender-specific Prevalence of Migraine in the EU5 (2019–2032)

Table 15: Diagnosed Cases of Episodic and Chronic Migraine in the EU5 (2019–2032)

Table 16: Prevalence of Migraine in Japan thousands (2019–2032)

Table 17: Prevalent Cases of Migraine by severity in Japan (2019–2032)

Table 18: Gender-specific Prevalence of Migraine in Japan (2019–2032)

Table 19: Diagnosed Cases of Episodic and Chronic Migraine in Japan (2019–2032)

Table 20: Zavegepant, Clinical Trial Description, 2022

Table 21: Atogepant, Clinical Trial Description, 2022

Table 22: INP104, Clinical Trial Description, 2021

Table 23: Zolmitriptan transdermal, Clinical Trial Description, 2022

Table 24: AXS-07, Clinical Trial Description, 2021

Table 25: Lu AG09222, Clinical Trial Description, 2022

Table 26: ABP-450, Clinical Trial Description, 2022

Table 27: IONIS-PKKRx, Clinical Trial Description, 2022

Table 28: IONIS-PKKRx, Clinical Trial Description, 2022

Table 29: LY-3451838, Clinical Trial Description, 2022

Table 30: 7 Major Market Size of Migraine in USD Million (2019–2032)

Table 31: United States Total Market Size of Migraine in USD Million (2019–2032)

Table 32: United States Market Size of Episodic Migraine by preventive Therapies in USD Million (2019–2032)

Table 33: United States Market Size of Episodic Migraine by Therapies in USD Million (2019–2032)

Table 34: United States Market Size of Chronic Migraine by preventive Therapies in USD Million (2019–2032)

Table 35: United States Market Size of Chronic Migraine by Acute therapies in USD Million (2019–2032)

Table 36: The EU-5 Market Size of Migraine in USD Million (2019–2032)

Table 37: Germany Market Size of Episodic Migraine for preventive Therapies in USD Million (2019–2030)

Table 38: The EU-5 Market Size of Episodic Migraine for Acute Therapies in USD Million (2019–2032)

Table 39: The EU-5 Market Size of Chronic Migraine for preventive Therapies in USD Million (2019–2032)

Table 40: The EU-5 Market Size of Chronic Migraine for Acute Therapies in USD Million (2019–2032)

Table 41: Japan Market Size of Migraine in USD Million (2019–2032)

Table 42: Japan Market Size of Migraine by Therapies in USD Million (2019–2032)

Table 43: Japan Market Size of Migraine by Therapies in USD Million (2019–2032)

Table 44: Japan Market Size of Migraine by Therapies in USD Million (2019–2032)

Table 45: Japan Market Size of Migraine by Therapies in USD Million (2019–2032)

List of Figures

Figure 1: Multiple factors contribute to migraine chronification

Figure 2: Algorithmic approach to diagnosing migraine

Figure 3: Multiple factors contribute to migraine chronification

Figure 4: Total Prevalent Population of Migraine in 7MM (2019–2032)

Figure 5: Prevalence of Migraine in the United States (2019–2032)

Figure 6: Prevalent Cases of Migraine by severity in the United States (2019–2032)

Figure 7: Gender-specific Prevalence of Migraine in the United States (2019–2032)

Figure 8: Diagnosed Cases of Episodic and Chronic Migraine in the United States (2019–2032)

Figure 9: Prevalence of Migraine in the EU5 (2019–2032)

Figure 10: Prevalent Cases of Migraine by severity in the EU-5 (2019–2032)

Figure 11: Gender-specific Prevalence of Migraine in the EU5 (2019–2032)

Figure 12: Diagnosed Cases of Episodic and Chronic Migraine in the EU5 (2019–2032)

Figure 13: Prevalence of Migraine in Japan (2019–2032)

Figure 14: Prevalent Cases of Migraine by severity in Japan (2019–2032)

Figure 15: Gender-specific Prevalence of Migraine in Japan (2019–2032)

Figure 16: Diagnosed Cases of Episodic and Chronic Migraine in Japan (2019–2032)

Figure 17: 7 Major Market Size of Migraine in USD Million (2019–2032)

Figure 18: Total Market Size of Migraine in the United States, USD Million (2019–2032)

Figure 19: The United States Market Size of Episodic Migraine by preventive Therapies in USD Million

Figure 20: The United States Market Size of Episodic Migraine by Acute Therapies in USD Million

Figure 21: The United States Market Size of Chronic Migraine by preventive Therapies in USD Million (2019–2032)

Figure 22: The United States Market Size of Chronic Migraine by Acute Therapies in USD Million

Figure 23: Total Market Size of Migraine in the EU-5, USD Million (2019–2032)

Figure 24: The Germany Market Size of Episodic Migraine for preventive Therapies in USD Million (2019–2032)

Figure 25: The EU-5 Market Size of Episodic Migraine for Acute Therapies in USD Million

Figure 26: The EU-5 Market Size of Chronic Migraine for preventive Therapies in USD Million

Figure 27: The EU-5 Market Size of Chronic Migraine for Acute Therapies in USD Million

Figure 28: Market Size of Migraine in Japan, USD Million (2019–2032)

Figure 29: Japan Market Size of Migraine by Therapies in USD Million (2019–2032)

Figure 30: Japan Market Size of Migraine by Therapies in USD Million (2019–2032)

Figure 31: Japan Market Size of Migraine by Therapies in USD Million (2019–2032)

Figure 32: Japan Market Size of Migraine by Therapies in USD Million (2019–2032)

Lundbeck Seattle BioPharmaceutical
Eli Lilly and Company
Amgen
Novartis
Teva Pharmaceuticals
Allergan
Biohaven Pharmaceuticals
Dr. Reddy’s Labs
AbbVie
Impel NeuroPharma
Zosano Pharma
Axsome Therapeutics
Aeon Biopharma Inc.
Ionis Pharmaceuticals, Inc.
Charleston Laboratories

 

Forward to Friend

Need A Quote